960 x 350_41

Small and Large Molecule LC-MS

Accurately measuring and quantifying biomarkers in relevant matrices informs numerous aspects of clinical drug development. Biomarker assays can match patients to appropriate therapies and demonstrate a candidate drugs safety and efficacy, thus illuminating its potential for clinical and commercial success. Q2 Solutions offers a wide range of tailored and integrated liquid chromatography mass spectrometry services to support biomarker testing and quantitation, including LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC-MS assays, small molecule LC/MS, and large molecule bioanalysis.

Our team has extensive experience developing and validating multiplex LC/MS assays of endogenous analytes (e.g., proteins, peptides, lipids) and small/large molecules and their metabolites. Q2 Solutions’ LC/MS/MS bioanalytical services are GLP and GCP compliant to support FDA, OECD, MHLW, and ICH standards.

Related Thought Leaders Insights


Preparation for Biotech Testing or Clinical Trials

Your clinical trial may involve samples from multiple sites to be tested by multiple laboratories. The data that flows from those tests may travel to multiple end users as well. Proper planning of...

Risk Management for Biotech Companies in Clinical Trials

  In this episode, the second of a three-part series, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Alan Wookey, Global Head of Companion Diagnostics discuss how to manage...

Bridging the Ligand Binding Assays and LC-MS Disciplines for Hybrid Assays

Assessing the pharmacokinetics of biologics presents several analytical challenges, from the use of critical reagents and assay sensitivity requirements to regulatory and throughput considerations....